Artemisinin and its derivatives are widely recognized for their exceptional antimalarial efficacy. Recently, accumulating evidence indicates therapeutic potential beyond malaria. Despite these advances, detailed mechanisms and pharmacological limitations remain incompletely defined. This review summarizes their pharmacological activities and molecular mechanisms associated with oncology, immunoregulation, and metabolic disorders. Mechanistically, these compounds exert potent antitumor effects by inducing oxidative stress, arresting the cell cycle, triggering apoptosis, and inhibiting angiogenesis. They likewise modulate immune responses, re-establishing immune homeostasis and enhancing the effectiveness of immunotherapeutic strategies. Preliminary evidence also suggests involvement in metabolic regulation, pointing to promising avenues for treating metabolic disorders. Given alternative mechanisms of artemisinin and its derivatives, we also discuss the trinity modulation network among antitumor activity, immunoregulation, and metabolic homeostasis. We anticipate that future research will address these knowledge gaps, thereby enhancing the clinical utility of artemisinin and its derivatives and improving patient outcomes across diverse pathologies.
Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, primarily characterized by reproductive dysfunction, insulin resistance (IR), and long-term metabolic complications. Current first-line pharmacological treatments, including oral contraceptives, anti-androgens, and insulin sensitizers, can alleviate clinical symptoms but often fail to fully address the underlying pathophysiology, and their long-term use is frequently limited by adverse effects. Natural products, owing to their multi-target regulatory properties and favorable safety profiles, have emerged a promising adjuvant therapeutic strategy. This review systematically summarizes how natural products exert beneficial effects through mechanisms such as improving metabolic homeostasis by enhancing insulin sensitivity and mitigating oxidative stress and chronic inflammation; restoring endocrine balance by modulating the hypothalamic–pituitary–gonadal axis to reduce hyperandrogenemia and promote ovulation; and utilizing emerging pathways including regulating gut microbiota homeostasis and epigenetic modifications as a novel avenue for PCOS drug development. Preclinical and clinical evidence collectively indicates that these agents hold significant translational potential to ameliorate metabolic disturbances and improve reproductive outcomes, providing a scientific foundation for future integrated intervention strategies in PCOS.
Background: Oxidative stress is a primary driver of neuronal injury in neurodegenerative conditions including ischemia stroke (IS). Icariin (ICA), a natural flavonoid, exhibits neuroprotective activity. However, its direct molecular target remains elusive. Here, we identified the direct protein target of ICA and elucidated the downstream pathways mediating its protection against hydrogen peroxide (H 2 O 2 )-induced neuronal injury. Methods: Neuronal B35 cells were treated with H 2 O 2 to induce oxidative stress. Cell viability was evaluated using CCK-8 assays and Calcein-AM/PI double staining. The direct binding target of ICA was screened by drug affinity responsive target stability-mass spectrometry (DARTS-MS) proteomics, followed by validation through molecular docking, molecular dynamics (MD) simulations as well as cellular thermal shift assay coupled with Western blot (CETSA-WB). RNA sequencing (RNA-seq) was performed to identify involved the signaling pathways. Network pharmacology and machine learning approaches including LASSO, random forest, and support vector machine, were applied to identify hub genes associated with IS. Finally, WB, phalloidin staining and siRNA-mediated FARP2 knockdown rescue experiments were performed to confirm the effects and mechanism of icariin in IS. Results: ICA dose-dependently restored B35 cell viability following H 2 O 2 exposure. FARP2 was identified as a direct binding target of ICA. Molecular docking and MD stimulations validated stable ICA-FARP2 binding (ΔG_bind = −21.38 ± 2.19 kcal/mol) driven by van der Waals and electrostatic interactions with Thr914 and Gln907. Transcriptomic profiling indicated that H 2 O 2 exposure upregulated RhoGTPase signaling, extracellular matrix organization, and cilium assembly pathways. Integrated analyses further identified caspase-3 as a core regulatory gene and implicated Rap1 and PI3K-Akt signaling in IS. Finally, the functional validation confirms that FARP2 siRNA blocks the protective effect of icariin against H 2 O 2 -induced B35 cell injury. Conclusion: ICA exerts neuroprotective effects against H 2 O 2 -induced neuronal injury by targeting FARP2 and modulating RhoGTPase and PI3K-Akt signaling, suggesting its potential in regulating cytoskeletal dynamics and cellular stress responses.